Alembic Pharmaceuticals has informed that it has enclosed press release titled, ‘Alembic Pharmaceuticals receives USFDA Final Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 m’.
The above information is a part of company’s filings submitted to BSE.